Journal
NATURE REVIEWS MICROBIOLOGY
Volume 9, Issue 1, Pages 62-75Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrmicro2474
Keywords
-
Categories
Funding
- US National Institutes of Health [R01AI062415, ARRA 1 R01AI079653]
- American Lebanese Syrian Associated Charities (ALSAC)
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062415, R01AI079653] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Persistent infections involving slow-growing or non-growing bacteria are hard to treat with antibiotics that target biosynthetic processes in growing cells. Consequently, there is a need for antimicrobials that can treat infections containing dormant bacteria. In this Review, we discuss the emerging concept that disrupting the bacterial membrane bilayer or proteins that are integral to membrane function (including membrane potential and energy metabolism) in dormant bacteria is a strategy for treating persistent infections. The clinical applicability of these approaches is exemplified by the efficacy of lipoglycopeptides that damage bacterial membranes and of the diarylquinoline TMC207, which inhibits membrane-bound ATP synthase. Despite some drawbacks, membrane-active agents form an important new means of eradicating recalcitrant, non-growing bacteria.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available